πŸ‡ΊπŸ‡Έ FDA

Intelligence Β· Clinical Pipeline

First People's Hospital Pipeline

All ClinicalTrials.gov programs at First People's Hospital β€” phase, modality, and trial IDs.

Programs
149

Quick answer

First People's Hospital has 149 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

  1. 18F-FAPIBiotin

    The First People's Hospital of Lianyungang

    Malignant Neoplasm

    phase 1 small molecule active

    1 trial

  2. 18F-FDG

    The First People's Hospital of Lianyungang

    Multiple Myeloma and Malignant Plasma Cell Neoplasms

    phase 1 small molecule active

    1 trial

  3. 68Ga-AAZTA-NI-093

    The First People's Hospital of Lianyungang

    Prostate Cancer (Adenocarcinoma)

    phase 1 small molecule active

    1 trial

  4. 68Ga-BNU-PSMA

    The First People's Hospital of Lianyungang

    Tumor

    phase 1 other active

    1 trial

  5. 68Ga-DOTA-FAPI, 177Lu-DOTA-FAPI

    The First People's Hospital of Lianyungang

    177Lu-DOTA-FAPI

    phase 1 small molecule active

    1 trial

  6. 68Ga-DOTA/NOTA-FAPI-04

    The First People's Hospital of Lianyungang

    Tumor

    phase 1 small molecule active

    1 trial

  7. 68Ga-FAPI-04

    The First People's Hospital of Lianyungang

    Liver Fibrosis

    phase 1 small molecule active

    1 trial

  8. 68Ga-FAPI-Biotin

    The First People's Hospital of Lianyungang

    Tumor

    phase 1 small molecule active

    1 trial

  9. 68Ga-JH04

    The First People's Hospital of Lianyungang

    Malignant Neoplasm

    phase 1 small molecule active

    1 trial

  10. 68Ga-JH12

    The First People's Hospital of Lianyungang

    Malignant Neoplasm

    phase 1 small molecule active

    1 trial

  11. 68Ga-MGS5

    The First People's Hospital of Lianyungang

    Medullary Thyroid Carcinoma

    phase 1 small molecule active

    1 trial

  12. 68Ga-NODAGA-SNA006

    The First People's Hospital of Lianyungang

    Solid Tumor

    phase 1 mab completed

    1 trial

  13. 68Ga-NOTA-MAL-Cys39-exendin-4

    The First People's Hospital of Lianyungang

    Insulinoma

    phase 1 small molecule active

    1 trial

  14. 68Ga-PSMA-11

    The First People's Hospital of Lianyungang

    Prostate Cancer

    phase 1 small molecule active

    1 trial

  15. 68Ga-Pentixafor

    The First People's Hospital of Lianyungang

    Lymphoma

    phase 1 small molecule active

    1 trial

  16. 99mTc-QULIC-5-P1

    The First People's Hospital of Lianyungang

    Prostate Cancer Stage

    phase 1 small molecule active

    1 trial

  17. A-CAR028

    The First People's Hospital of Lianyungang

    Acute Myeloid Leukemia (AML)

    phase 1 mab active

    1 trial

  18. AFN50 injection

    The First People's Hospital of Lianyungang

    Autoimmune Diseases

    phase 1 mab active

    1 trial

  19. ATHENA CAR-T

    The First People's Hospital of Lianyungang

    Lupus Erythematosus, Systemic

    phase 1 mab active

    1 trial

  20. Adebrelimab

    The First People's Hospital of Lianyungang

    Biliary Tract Malignancies

    phase 1 small molecule active

    1 trial

  21. Akk Gut Bacteria Supplement

    The First People's Hospital of Lianyungang

    Premature Ovarian Failure (POF)

    phase 1 other active

    1 trial

  22. All-trans retinoic acid

    The First People's Hospital of Lianyungang

    Acute Myeloid Leukemia

    phase 1 small molecule active

    1 trial

  23. Amitriptyline Hydrochloride 25Mg Tablet（Hunan DongtingοΌ‰

    The First People's Hospital of Lianyungang

    Depressive Disorder

    phase 1 small molecule completed

    1 trial

  24. Anlotinib hydrochloride,Penpulimab

    The First People's Hospital of Lianyungang

    Colorectal Cancer

    phase 1 small molecule active

    1 trial

  25. Anti-BCMA CAR-T cells

    The First People's Hospital of Lianyungang

    Multiple Myeloma

    phase 1 mab active

    1 trial

  26. Anti-CD19-CAR

    The First People's Hospital of Lianyungang

    Leukemia

    phase 1 mab active

    1 trial

  27. Anti-CD20 monoclonal antibody and the BTK inhibitor

    The First People's Hospital of Lianyungang

    Anti-CD20 Monoclonal Antibody

    phase 1 small molecule active

    1 trial

  28. BAO-G

    The First People's Hospital of Lianyungang

    Thoracoabdominal Aortic Aneurysm

    phase 1 other active

    1 trial

  29. Biological: LV009 injection

    The First People's Hospital of Lianyungang

    CD19+ Relapse/Refractory B-ALL

    phase 1 small molecule active

    1 trial

  30. CAR-BCMA T cells

    The First People's Hospital of Lianyungang

    Refractory or Relapsed Multiple Myeloma

    phase 1 gene therapy active

    1 trial

  31. CAR-T cell infusion

    The First People's Hospital of Lianyungang

    Hematolymphoid Malignancies

    phase 1 small molecule active

    1 trial

  32. CAR-T cells Infusion chimeric antigen receptor T cells

    The First People's Hospital of Lianyungang

    Relapsed/Refractory Plasma Cell Leukemia

    phase 1 small molecule active

    1 trial

  33. CARTmeso CART19

    The First People's Hospital of Lianyungang

    Pancreatic Cancer

    phase 1 mab active

    1 trial

  34. CBG131 CAR-T Cell Infusion

    The First People's Hospital of Lianyungang

    Advanced Gastric and Pancreatic Cancer

    phase 1 small molecule active

    1 trial

  35. CD19 and BCMA-targeted allogeneic CAR-T cells

    The First People's Hospital of Lianyungang

    Refractory Immune-mediated Platelet Transfusion Refractoriness

    phase 1 gene therapy active

    1 trial

  36. CD19/BCMA-Targeted Universal Chimeric Antigen Receptor T Cells (UCAR-T) infusing

    The First People's Hospital of Lianyungang

    Refractory Idiopathic Membranous Nephropathy

    phase 1 small molecule active

    1 trial

  37. CS-101

    The First People's Hospital of Lianyungang

    Beta-Thalassemia

    phase 1 mab completed

    1 trial

  38. CT-996

    The First People's Hospital of Lianyungang

    Type 2 Diabetes

    phase 1 small molecule completed

    1 trial

  39. CTA101

    The First People's Hospital of Lianyungang

    Diffuse Large B-cell Lymphoma

    phase 1 mab active

    1 trial

  40. CVA

    The First People's Hospital of Lianyungang

    Acute Myeloid Leukemia

    phase 1 small molecule active

    1 trial

  41. Chimeric antigen receptor T cell

    The First People's Hospital of Lianyungang

    Pancreatic Cancer

    phase 1 small molecule active

    1 trial

  42. Chinese Herbal Compound Ointment

    The First People's Hospital of Lianyungang

    Atrophic Vaginitis

    phase 1 small molecule active

    1 trial

  43. ClinOleic (Baxter Healthcare, Deerfield, IL, USA)

    The First People's Hospital of Lianyungang

    Nutritional Supplement Toxicity

    phase 1 small molecule active

    1 trial

  44. Conditioning chemotherapy followed by AbTCR (anti-CD19/CD22)-T cell infusion

    The First People's Hospital of Lianyungang

    Diffuse Large B Cell Lymphoma (DLBCL)

    phase 1 small molecule active

    1 trial

  45. Dexlansoprazole Injection

    The First People's Hospital of Lianyungang

    Effect of Drugs

    phase 1 small molecule active

    1 trial

  46. Dexmedetomidine

    The First People's Hospital of Lianyungang

    Cesarean Section, Affecting Fetus or Newborn

    phase 1 small molecule completed

    1 trial

  47. Dexmedetomidine

    The First People's Hospital of Lianyungang

    Heart Injuries

    phase 1 small molecule active

    1 trial

  48. Digoxin

    The First People's Hospital of Lianyungang

    Healthy

    phase 1 small molecule completed

    1 trial

Frequently asked questions

How many pipeline programs does First People's Hospital have?

149 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This hub lists all published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Data attribution: Data sources Β· All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates β€” weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.